hVIVO PLC reported annual revenue of £46.7 million, which met market expectations, prompting City brokers to evaluate whether the clinical research organisation has begun to reverse its fortunes after a
hVIVO plc (AIM: HVO) Trading Update
FY25 revenue in line and positive adjusted EBITDA Positioned to return to growth in 2026
Poolbeg Pharma (AIM: POLB) POLB 001 LPS Challenge Trial Paper Published
Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
hVIVO plc (AIM: HVO) Notice of Trading Update
Notice of Trading Update
Poolbeg Pharma (AIM: POLB) Letter to Shareholders – 2025 a year of progress
Letter to Shareholders – 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected
Poolbeg Pharma (AIM: POLB) POLB 001 to feature in CRS research programme
POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part
hVIVO plc (AIM: HVO) plays key role in $9.2bn Cidara takeover by MSD
hVIVO plc has highlighted a major validation of its clinical capabilities after its client Cidara Therapeutics agreed to be acquired by pharmaceutical giant MSD in a deal worth approximately $9.2
Poolbeg Pharma (AIM: POLB) secures European patent for POLB 001
Poolbeg Pharma (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II
hVIVO plc (AIM: HVO) secures £5m+ in new clinical trial contracts
hVIVO plc has announced that its German subsidiary, CRS, has landed more than £5 million in new contracts since September, driven in large part by two returning mid-sized German pharmaceutical
hMPV Interview with Guy Boivin & hVIVO’s Chief Scientific Officer
Join us for an insightful conversation on hMPV featuring our Chief Scientific Officer, Dr Andrew Catchpole and Guy Boivin, a professor from Laval University and one of the founding fathers
hVIVO plc: Diversification in Action as 2026 Growth Beckons
After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November
hVIVO plc: Diversification in Action as 2026 Growth Beckons
After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November